Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 8/20 | 0.56 |
| ▸ | ADRA1D known ✓ | P25100 | 7/20 | 0.56 |
| ▸ | ADRA1B known ✓ | P35368 | 7/20 | 0.56 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7690863 | 0.98 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL7671076 | 0.84 | DRD2 (0.63) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL5240356 | 0.84 | ADRA1D (0.52) | ADRA1AADRA1DADRA1B | |
| SCHEMBL6193262 | 0.84 | ADRA1A (0.55) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL14621895 | 0.81 | DRD2 (0.67) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL7301761 | 0.80 | ADRA1A (0.60) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL3955000 | 0.79 | ADRA1D (0.58) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL3954997 | 0.79 | ADRA1D (0.58) | ADRA1AADRA1DADRA1BHTR1A | |
| Ethylamine SCHEMBL7690866 | 0.77 | HTR6 (0.59) | ADRA1AADRA1DADRA1BHTR1A | |
| SCHEMBL3867980 | 0.76 | HTR6 (0.68) | ADRA1AADRA1DADRA1BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082421-A1 | Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082421-A1 | Novel solid salt forms of N-[2-[4-[2-(1- methylethoxy)phenyl]-1-piperazinyl]-2-oxo-1piperidineacetamide | NPPA, SCN2A, SLC28A2 | ADRA1A 1124/4885ADRA1D 1058/4885ADRA1B 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.